Table 1.
Baseline Characteristics Between the Eplontersen Group and Control Group*
| Characteristic | Eplontersen group (n=6) | Control group (n=7) | P value |
|---|---|---|---|
| Age, y | 59.33±5.538 | 62.43±6.214 | 0.517 |
| Male sex | 5 (83.3) | 5 (71.4) | 0.626 |
| BMI, kg/m2 | 23.26±1.832 | 22.53±3.398 | 0.937 |
| NYHA Fc I‐II | 6 (100) | 7 (100) | 1.000 |
| Follow‐up duration, d | 607.51 [526–850] | 491.00 [195–644] | 0.445 |
| Genetics | |||
| Ala97Ser (A97S) | 6 (100) | 6 (86) | |
| Glu89Lys (E89K) | 0 (0) | 1 (14) | |
| Biochemistry | |||
| Platelets, k/μL | 214.50±28.877 | 195.00±38.792 | 0.394 |
| NT‐proBNP, pg/mL | 374.90 [69–4271] | 470.60 [176–1286] | 0.886 |
| Creatinine, mg/dL | 0.83±0.197 | 0.73±0.206 | 0.306 |
| eGFR, mL/min per 1.73 m2 | 100.22±20.857 | 116.27±38.532 | 0.475 |
| Echocardiography | |||
| LV ejection fraction, % | 63.33±11.572 | 63.03±11.330 | 0.873 |
| IVS thickness, mm | 14.67±2.422 | 13.77±4.809 | 0.744 |
| LV posterior wall thickness, mm | 13.50±1.517 | 12.68±3.007 | 0.807 |
| LV end‐diastolic diameter, mm | 43.00±4.243 | 46.17±5.492 | 0.296 |
| LV mass index, g/m2 | 141.30±43.645 | 148.80±39.222 | 0.831 |
| LVGLS, % | −15.40±4.489 | −15.78±3.056 | 0.866 |
BMI indicates body mass index; eGFR, estimated glomerular filtration rate; IVS, interventricular septal; LV, left ventricular; LVGLS, left ventricular global longitudinal strain; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; and NYHA Fc, New York Heart Association functional classification.
*
Data are given as mean±SD, number (percentage), or median [first quartile–third quartile].